Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in research ...

Diagnosed with mild cognitive impairment (MCI) in 2018, Mr Almond, from Esher, took part in two 18-month trials for donanemab ...

Donanemab, the most effective treatment yet for the disease, has been banned on the health service despite regulators ...

NICE has said the Alzheimer's disease drug is too expensive to be available on the NHS, but researchers are now hoping to ...

The UK’s National Institute of Health and Care Excellence (NICE) said the drug provided only a small benefit to patients.

UK MHRA grants marketing approval to Lilly's Kisunla to treat mild cognitive impairment and mild dementia due to Alzheimer's disease: Indianapolis Thursday, October 24, 2024, 09:0 ...

The drug is the second Alzheimer’s medicine to receive a lukewarm reception from the UK government in recent months.View on ...

If I were a statistician tucked away in an NHS backroom, I might well curse the day the health service was founded. There, on ...

Health spending watchdog said costs could not justify benefits after treatment slowed cognitive decline by around four to ...

While Ruth may be in good health, her confession of fearing Alzheimer's comes just days after the NHS announced it wouldn't ...